Degarelix approved for clinical trial testing by the VA – June, 2020

Buildings from below
Caption One

Since February, we have pivoted our focus towards finding therapeutics to treat and prevent COVID19. One category of therapeutics we identified early on were anti-androgenic compounds, which have been shown to down regulate TMPRSS2, a key host protease important in viral infection. Degarelix falls into this anti-androgenic class of therapeutics, and has been previously FDA-approved as a hormonal regulator to treat prostate cancer. Our recommendation of Degarelix to The U.S. Department of Veterans Affairs has led to the development of clinical trials at multiple hospitals across the nation.

Leave a Reply

Your email address will not be published. Required fields are marked *